Drugs / Pentostatin
Pentostatin
also known as
Nipent · Deoxycoformycin · 2'-Deoxycoformycin · CI-825 · DCF · NSC 218321 · PD 81565 · Pentostatin - Nipent · +3 more
Small molecule targets ADA via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NIPENT | — | 1993-09-29 | fda.gov ↗ |
| Approved | US (FDA) | NIPENT | — | 1991-10-11 | fda.gov ↗ |
Trials 47 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05470491 Background | Jan 2023 → Jul 2026 overdue | HIV infectious disease, hematopoietic and lymphoid cell neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02032446 Background | Sep 2013 → Sep 2016 | hematopoietic and lymphoid cell neoplasm | A.O. Ospedale Papa Giovanni XXIII | Unknown | No outcome recorded |
| Phase 1/2 | NCT00709215 Background | Jun 2008 → Dec 2010 | acute lymphoblastic leukemia | OncoVista, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT00546377 Background | Jul 2005 → May 2014 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03663933 Background | Sep 2018 → Apr 2025 overdue | T-cell immunodeficiency, autoimmune lymphoproliferative syndrome, common variable immunodeficiency | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02694770 Comparator | Jul 2016 → Sep 2017 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Withdrawn | No outcome recorded |
| Phase 2 | NCT00816595 Background | Feb 2009 → Jul 2013 | leukemia, lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00402714 Comparator | Jul 2006 → Jul 2009 | hematopoietic and lymphoid cell neoplasm | Yale University | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06821542 Background | Jun 2025 → May 2028 expected | chronic graft versus host disease | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03112603 Comparator | Jun 2017 → May 2020 | chronic graft versus host disease | Incyte Corporation | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 59 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pentostatin | “Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone...” NCT01460602 ↗52“Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)” NCT02579967 ↗ “such as Etanercept and infliximab, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis” NCT02694770 ↗ “Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days.” NCT02032446 ↗ “pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4)” NCT00676806 ↗ “Pentostatin 4 mg/m2/day IV on days -11 and -7.” NCT05470491 ↗ “pentostatin 4 mg/m2/day IV on days -11 and -7” NCT03922724 ↗ “Pazopanib, Pentostatin, Romidepsin” NCT02788201 ↗ “Pazopanib Pentostatin Ponatinib” NCT02551718 ↗ “• Pentostatin” NCT06821542 ↗ |
| Known as | 2'-Deoxycoformycin | “A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia” NCT00003005 ↗ |
| Known as | CI-825 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | DCF | “Deoxycoformycin (DCF)” NCT00038025 ↗ |
| Known as | Deoxycoformycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003005 ↗ |
| Known as | Nipent | “Pentostatin (Nipent®) and Alemtuzumab (Campath®)” NCT00698685 ↗ |
| Known as | NSC 218321 | “A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia” NCT00003005 ↗ |
| Known as | PD 81565 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | Pentostatin - Nipent | “Pentostatin - Nipent” NCT01001780 ↗ |
| Known as | Pentostatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | Pentostatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Known as | YK-176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1580 ↗ |
| Action | Inhibit | “the adenosine deaminase inhibitor pentostatin” NCT00003005 ↗ |
| Modality | Small molecule | “purine nucleoside analogue” PMID 20187101 ↗ May 2010 |
| Route | Intravenous | “pentostatin is administered over 5 minutes by IV bolus” NCT00003005 ↗ |
| Target | ADA | “It is a potent inhibitor of the enzyme adenosine deaminase (ADA)” NCT00496340 ↗ |